Literature DB >> 4769695

Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum.

U Gundert-Remy, M Klett, E Weber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4769695     DOI： 10.1007/bf00562440

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  THE ABSORPTION, EXCRETION, AND METABOLIC FATE OF ETHAMBUTOL IN MAN.

Authors:  E A PEETS; W M SWEENEY; V A PLACE; D A BUYSKE
Journal:  Am Rev Respir Dis       Date:  1965-01

2.  Clinical pharmacology of ethambutol.

Authors:  V A PLACE; J P THOMAS
Journal:  Am Rev Respir Dis       Date:  1963-06

3.  The blood-cerebrospinal fluid barrier in man.

Authors:  D P RALL; E MOORE; N TAYLOR; C G ZUBROD
Journal:  Arch Neurol       Date:  1961-03

4.  [Cerebrospinal fluid patency of ethambutol].

Authors:  U Gundert-Remy; E Weber; M Klett
Journal:  Verh Dtsch Ges Inn Med       Date:  1972

5.  Ethambutol in tuberculous meningitis.

Authors:  I D Bobrowitz
Journal:  Chest       Date:  1972-06       Impact factor: 9.410

6.  Ethambutol in tuberculous meningitis.

Authors:  V A Place; M M Pyle; J De la Huerga
Journal:  Am Rev Respir Dis       Date:  1969-05

7.  Metabolic and special studies of ethambutol in normal volunteers and tuberculous patients.

Authors:  V A Place; E A Peets; D A Buyske; R R Little
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

8.  [Ethambutol levels in diverse dosage: comparison of different determination methods].

Authors:  H Eule; E Werner
Journal:  Z Erkr Atmungsorgane Folia Bronchol       Date:  1970-12

9.  Concentrations of ethambutol in the cerebrospinal fluid after oral administration.

Authors:  J A Pilheu; F Maglio; R Cetrangolo; A D Pleus
Journal:  Tubercle       Date:  1971-06
  9 in total
  11 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Protein Binding of First-Line Antituberculosis Drugs.

Authors:  Wael A Alghamdi; Mohammad H Al-Shaer; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

4.  Binding of rifampicin by human plasma proteins.

Authors:  G Boman; V A Ringberger
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

6.  Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 7.  Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe.

Authors:  Alyssa Mezochow; Kiran Thakur; Christopher Vinnard
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09-20       Impact factor: 5.081

Review 8.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 9.  Clinical pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

10.  Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.

Authors:  R M Savic; R Ruslami; J E Hibma; A Hesseling; G Ramachandran; A R Ganiem; S Swaminathan; H McIlleron; A Gupta; K Thakur; R van Crevel; R Aarnoutse; K E Dooley
Journal:  Clin Pharmacol Ther       Date:  2015-10-22       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.